Experts say the drug industry should use the opportunity provided in recent US Food and Drug Administration guidance to volunteer information the agency can use in lieu of site inspections it cannot conduct due to the coronavirus pandemic.
The idea is that new types of information could help persuade the FDA to approve applications without inspecting manufacturing sites...




